Skip to main content

Clinical trial OX2016-203-01

An open-label, dose-escalation, phase I study to assess the safety, pharmacokinetics and pharmacodynamics of AsiDNA, a DNA repair inhibitor administered intravenously in patients with advanced solid tumors

Cancers
Organ Multiples
Trial status Trial open for recruitment
Investigator
Trial type
Interventionnal with IMP
Phase Trial phase 1
Academic trial Non
Sponsor Onxeo
EudraCT Identifier 2017-000088-34
ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03579628
Inclusion criteria Any line/RECIST v1.1/Eligible for platinium salt chemotherapy
Last update